Table 2 Clinical outcome
Groups | Trial I | Trial II | ||
|---|---|---|---|---|
BV EcoVag® | Group-1 BV EcoVag® | Group-2 VVC EcoVag® | Group-3 VVC No EcoVag® | |
Patients enrolled | 10 | 11 | 9 | 10 |
Patients lost to follow up | 2 (no. 5 and 20)a | 2 (no. 12, 19) | 0 | 0 |
Patients analyzed | 8 | 9 | 9 | 10 |
Patients cured at 6-months | 4 (50 %) | 6 (67 %) | 9 (100 %) | 10 (100 %) |
Patients cured at 12-months | 4 (50 %) | 6 (67 %) | 8 (89 %) | 7 (70 %) |
Relapses (identification number) | 4 (no. 1, 2, 7, 8) | 3 (no. 2, 4, 17) | 0 | 3 (no. 23, 25, 28) |
Patients with new sexual partner on follow up | 2 (no. 2, 7)b | 3 (no. 2, 4, 17) | 1 (no. 7) | 0 |
New sexual partner before relapses of BV | 2 (no. 2, 7) | 3 (no. 2, 4, 17) | 0 | 0 |
Chlamydia infection | 0 | 1 (no. 4) | 0 | 0 |
Surgical abortion and post-operative infection | 0 | 1 (no. 17) | 0 | 0 |
Both BV and VVC | 0 | 1 (no. 15)c | 0 | 0 |